NASDAQ$TVTX
Travere Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Travere reported Q4 2023 financial results, highlighted by FILSPARI's commercial progress and the initiation of the Phase 3 pegtibatinase program.
Travere Therapeutics reported Q4 2023 net product sales of $39.9 million, driven by FILSPARI. The company is advancing its pipeline, including a Phase 3 study for pegtibatinase. The company had $566.9 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
- Received 459 new patient start forms (PSFs) for FILSPARI in Q4 2023, with a total of 1,452 PSFs received in 2023.
- Net product sales for Q4 2023 were $39.9 million, and $127.5 million for FY 2023.
- Company is nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval.
- Pivotal Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria (HCU) is enrolling, with topline data anticipated in 2026.
Headline financials
Revenue & EPS history
Travere · Revenue · Quarterly
$45.1M
Revenue by segment
Travere · $33.9M total across 2 segments · Q3 2023
- Tiopronin products$25.9M+2.0%76.3%
- FILSPARI$8.04M—23.7%
Forward guidance
Travere Therapeutics looks forward to further strengthening the U.S. commercial launch of FILSPARI in IgAN, potential full approval of FILSPARI, anticipated inclusion into global treatment guidelines for IgAN, and advancing the Phase 3 HARMONY Study of pegtibatinase.
Tailwinds
- Furthering the strength of the U.S. commercial launch of FILSPARI in IgAN.
- Potential full approval of FILSPARI.
- Anticipated inclusion into the global treatment guidelines for IgAN.
- Additional data planned in 2024.
- Advancing the innovative Phase 3 HARMONY Study of pegtibatinase.
Headwinds
- Risks associated with regulatory review and approval process.
- Risks associated with market acceptance of commercial products.
- Uncertainties related to patent protection and exclusivity periods.
- Risks associated with regulatory interactions.
- Risks and uncertainties relating to competitive products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-0.3%
Avg return
30 days after
49%
25 / 51 earnings
Positive
+16.6%
Q3 2025
Best reaction
-16.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | -5.1% | +2.8% | |
| Q4 2025 | +3.1% | +0.1% | -8.4% | |
| Q3 2025 | +16.6% | +13.7% | +19.4% | |
| Q1 2025 | +1.6% | -2.6% | -27.6% | |
| Q4 2024 | -6.8% | -10.8% | -12.9% | |
| Q3 2024 | -1.1% | -0.0% | +5.9% | |
| Q2 2024 | -5.7% | -6.7% | -0.7% | |
| Q1 2024 | +7.8% | +0.6% | +25.1% | |
| Q4 2023 | -0.6% | +0.4% | -9.2% | |
| Q3 2023 | -4.7% | -16.0% | +30.3% | |
| Q2 2023 | -6.6% | -6.7% | -10.5% | |
| Q1 2023 | +5.6% | +4.2% | +19.7% | |
| Q4 2022 | +6.9% | +6.2% | +0.0% | |
| Q3 2022 | +3.1% | +0.5% | -12.4% | |
| Q2 2022 | +16.0% | +16.2% | +13.5% | |
| Q1 2022 | -14.2% | -13.2% | -6.4% | |
| Q4 2021 | +2.9% | +2.1% | -3.3% | |
| Q3 2021 | +10.0% | +15.1% | +10.8% | |
| Q2 2021 | -2.4% | +0.5% | +52.7% | |
| Q1 2021 | -16.6% | -17.4% | -41.2% | |
| Q4 2020 | -5.3% | -12.4% | -19.0% | |
| Q3 2020 | +1.6% | +11.4% | +18.1% | |
| Q2 2020 | -1.6% | -4.1% | -4.3% | |
| Q1 2020 | +7.6% | +0.8% | -0.9% | |
| Q4 2019 | -16.7% | -10.3% | -21.4% | |
| Q3 2019 | +4.4% | +8.0% | +20.7% | |
| Q2 2019 | -11.4% | -2.7% | -34.0% | |
| Q1 2019 | -7.9% | -5.5% | -2.7% | |
| Q4 2018 | +5.6% | +4.3% | +7.7% | |
| Q3 2018 | +0.6% | +1.2% | -4.4% | |
| Q2 2018 | -4.4% | -4.2% | +2.4% | |
| Q1 2018 | -5.2% | -5.7% | +11.6% | |
| Q4 2017 | +5.4% | +5.2% | -5.8% | |
| Q3 2017 | -13.4% | -16.3% | -17.1% | |
| Q2 2017 | -0.1% | +7.6% | +15.8% | |
| Q1 2017 | -4.4% | -6.5% | -7.1% | |
| Q4 2016 | +1.5% | -0.6% | -13.2% | |
| Q3 2016 | -4.3% | -1.2% | +8.5% | |
| Q2 2016 | +1.4% | -1.9% | -13.6% | |
| Q1 2016 | +5.2% | — | — | |
| Q4 2015 | -2.8% | — | — | |
| Q3 2015 | -10.0% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +5.8% | — | — | |
| Q4 2014 | +9.5% | — | — | |
| Q3 2014 | -14.4% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +4.9% | — | — | |
| Q4 2013 | +8.4% | — | — | |
| Q3 2013 | -5.8% | — | — | |
| Q2 2012 | -9.9% | — | — | |
| Q3 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro